Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:tapentadol
|
| gptkbp:approvalYear |
2010
|
| gptkbp:ATCCode |
N02AX06
|
| gptkbp:contraindication |
paralytic ileus
severe respiratory depression acute intoxication with alcohol |
| gptkbp:drugClass |
opioid
|
| gptkbp:eliminationHalfLife |
4 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
prolonged-release tablet
immediate-release tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Palexia
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
Grünenthal
|
| gptkbp:marketedIn |
gptkb:Australia
gptkb:Canada gptkb:Europe |
| gptkbp:mechanismOfAction |
norepinephrine reuptake inhibitor
mu-opioid receptor agonist |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
C (US) |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation dizziness somnolence |
| gptkbp:status |
approved in EU
|
| gptkbp:synonym |
gptkb:tapentadol
|
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:Tapentadol
|
| gptkbp:bfsLayer |
7
|